How clinical and research failures lead to suboptimal prescribing: The example of chronic gout

BMJ (Online)

Volumn 343, Issue 7835, 2011, Pages

  Lipworth, Wendy ^a,b   Kerridge, Ian ^b   Brett, Jonathan ^c   Day, Richard ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZOBROMARONE; COLCHICINE; FEBUXOSTAT; PROBENECID; UNCLASSIFIED DRUG; URICOSURIC AGENT;

CHRONIC DISEASE; CLINICAL PRACTICE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GOUT; HUMAN; HYPERSENSITIVITY REACTION; LIVER TOXICITY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE;

ALLOPURINOL; CHRONIC DISEASE; DRUG DISCOVERY; DRUG UTILIZATION; GOUT; GOUT SUPPRESSANTS; GUIDELINE ADHERENCE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROBENECID;

EID: 84859007371     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d7459     Document Type: Review

References (28)

1. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007;3:443-9. (Pubitemid 47193550)
2. Neogi T. Gout. N Engl J Med 2011;364:443-52.
3. Gutierrez-Macias A, Lizarralde-Palacios E, Martinez-Odriozola P, Miguel-De la Villa F. Lesson of the week. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ 2005;331:623-4. (Pubitemid 41360781)
4. Lee MHH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf 2008;31:643-65. (Pubitemid 352019563)
5. Hung SL, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102:4134-9. (Pubitemid 40388568)
6. Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: A retrospective analysis of administrative claims. J Rheumatol 2004;31:1575-81. (Pubitemid 39006640)
7. Roddy E, Zhang WY, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 2007;66:1311-5. (Pubitemid 47492473)
8. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology 2005;44:1038-42. (Pubitemid 41487179)
9. Reinders MK, van Roon EN, Jansen T, Delsing J, Griep EN, Hoekstra M, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009;68:51-6.
10. Reinders MK, Haagsma C, Jansen T, van Roon EN, Delsing J, de Laar M, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2009;68:892-7.
11. Harris CM, Lloyd D, Lewis J. Prevalence and prophylaxis of gout in England J Clin Epidemiol 1995;48:1153-8.
12. Krishnan E, Lienesch D, Kwoh CK. Gout in ambulatory care settings in the United States. J Rheumatol 2008;35:498-501. (Pubitemid 351374428)
13. Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis 2009;68:1265-70.
14. Perry ME, Madhok R. Treatment failure gout: failure to treat? Rheumatology 2010;49:2233-4.
15. Mikuls TR, MacLean CH, Olivieri J, Patino F, Allison JJ, Farrar JT, et al. Quality of care indicators for gout management. Arthritis Rheum 2004;50:937-43. (Pubitemid 38326194)
16. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl JR, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007;46:1372-4.
17. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity-description and guidelines for prevention in patients with real insufficiency Am J Med 1984;76:47-56. (Pubitemid 14216359)
18. Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, et al. Using Allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011;63:412-21.
19. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PAC, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282:1458-65. (Pubitemid 29493800)
20. Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009;11:R46.
21. Lindsay K, Gow P, Vanderpyl J, Logo P, Dalbeth N. The experience and impact of living with gout. A study of men with chronic gout using a qualitative grounded theory approach. J Clin Rheumatol 2011;17:1-6.
22. Reinders MK, Jansen TLTA. Management of hyperuricemia in gout: focus on febuxostat. Clin Interv Aging 2010;5:7-18.
23. Becker MA, Chohan S. We can make gout management more successful now. Curr Opin Rheumatol 2008;20:167-72. (Pubitemid 351339888)
24. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010;62:1060-8.
25. Kesselheim AS, Solomon DH. Incentives for drug development-the curious case of colchicine. N Engl J Med 2010;362:2045-7.
26. Flaker GC, Schutz J. Why is warfarin underutilized in patients with atrial fibrillation? J Interv Card Electrophysiol 2004;10:21-5.
27. United Kingdom Clinical Pharmacy Association. UKCPA position statement on the introduction of new oral anticoagulants for stroke prevention in atrial fibrillation. UKCPA, 2011.
28. Lipworth W, Wodak A, Haber P, Day R. Why is disulfiram not on the PBS? Med J Aust 2011;195:371-2.